Piezo1和Piezo2在肿瘤样本中的mRNA表达综合分析及其对胃癌的预后意义。
Comprehensive analysis of mRNA expression of Piezo1 and Piezo2 in tumor samples and their prognostic implications in gastric cancer.
作者信息
Liang Tong, Wang Junhong, Yang Zhong, Zhang Ronglong
机构信息
The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, Gansu, China.
Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu, China.
出版信息
Discov Oncol. 2025 Apr 21;16(1):582. doi: 10.1007/s12672-025-02309-5.
BACKGROUND
This study aims to investigate the expression pattern and clinical significance of Piezo1 and Piezo2 in various cancers, focusing on gastric cancer (GC).
METHODS
The study investigated the mRNA expression levels of Piezo1 and Piezo2 in tumor samples from different cancers using the BEST online database. The case-control studies about the relation between Piezo1 and Piezo2 and GC were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. The retrieval time was from inception to October, 2023. The meta-analysis of the included literatures was conducted by the STATA 12.0 software. Additionally, the expression profiles of Piezo1 and Piezo2 in tumor and normal gastric tissues were analyzed, and their clinical drug relevance was assessed using the CPADS database. The research program has been registered with PROSPERO (CRD42023495836).
RESULTS
The analysis demonstrated elevated mRNA expression of both Piezo1 and Piezo2 in the majority of tumor samples. Of particular note was the significant increase observed in GC tissue compared to normal tissue (all p < 0.05). Additionally, the meta-analysis revealed a meaningful correlation between high expression levels of Piezo1 and Piezo2 and poor prognosis in patients with GC (HR = 1.48, 95% CI = 1.27-1.69, p < 0.0001). This study identified a significant correlation between high levels of Piezo1 expression and the TNM phase (OR = 1.87, 95% CI = 1.21-2.91, p = 0.005). Furthermore, enhanced Piezo2 expression was observed to be positively correlated with survival status (OR = 2.12, 95% CI = 1.31-3.44, p = 0.002). Piezo1 (p = 0.028, R = 0.12) and Piezo2 (p = 0.049, R = 0.09) have been identified as potential therapeutic targets for GC treatment, according to drug sensitivity analyses.
CONCLUSION
The findings of this study indicate that the expression levels of Piezo1 and Piezo2 have the potential to serve as diagnostic indicators or therapeutic targets for GC management.
TRIAL REGISTRATION
CRD42023495836 (PROSPERO).
背景
本研究旨在探讨Piezo1和Piezo2在各种癌症中的表达模式及临床意义，重点关注胃癌（GC）。
方法
本研究使用BEST在线数据库调查了不同癌症肿瘤样本中Piezo1和Piezo2的mRNA表达水平。从PubMed、Embase、Web of Science和Cochrane图书馆检索了关于Piezo1和Piezo2与GC关系的病例对照研究。检索时间为从数据库建立至2023年10月。使用STATA 12.0软件对纳入文献进行荟萃分析。此外，分析了Piezo1和Piezo2在肿瘤和正常胃组织中的表达谱，并使用CPADS数据库评估了它们与临床药物的相关性。该研究方案已在PROSPERO（CRD42023495836）注册。
结果
分析表明，大多数肿瘤样本中Piezo1和Piezo2的mRNA表达均升高。特别值得注意的是，与正常组织相比，GC组织中观察到显著增加（所有p<0.05）。此外，荟萃分析显示，Piezo1和Piezo2的高表达水平与GC患者的不良预后之间存在有意义的相关性（HR=1.48，95%CI=1.27-1.69，p<0.0001）。本研究确定Piezo1的高表达水平与TNM分期之间存在显著相关性（OR=1.87，95%CI=1.21-2.91，p=0.005）。此外，观察到Piezo2表达增强与生存状态呈正相关（OR=2.12，95%CI=1.31-3.44，p=0.002）。根据药物敏感性分析，Piezo1（p=0.028，R=0.12）和Piezo2（p=0.049，R=0.09）已被确定为GC治疗的潜在治疗靶点。
结论
本研究结果表明，Piezo1和Piezo2的表达水平有可能作为GC管理的诊断指标或治疗靶点。
试验注册
CRD42023495836（PROSPERO）。
Zotero 插件